Basic Information
Bavencio
Regulatory Information
EMEA/H/C/004338
September 18, 2017
July 20, 2017
21
August 21, 2024
Company Information
the netherlands
Gustav Mahlerplein 102 1082 MA Amsterdam
Merck Europe BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.
Overview Summary
Bavencio is a cancer medicine used to treat adults with: - Merkel cell carcinoma (MCC, a type of skin cancer), when the cancer has spread to other parts of the body; - Renal cell carcinoma (RCC, a cancer of the kidney), when the cancer is advanced; Bavencio is used in combination with another cancer medicine, axitinib; - Urothelial carcinoma (a type of bladder cancer), when the cancer is locally advanced or has spread to other parts of the body in patients whose cancer had not got worse after platinum-based chemotherapy. Bavencio contains the active substance avelumab.